Does Amerigroup Cover Jardiance?

How Amerigroup Formulary Coverage Works for Jardiance

Amerigroup is a subsidiary of Elevance Health (formerly Anthem) that operates Medicaid managed care and Medicare Advantage plans in more than 20 states. Each state contract produces a distinct preferred drug list (PDL), so Jardiance's formulary placement is not uniform across all Amerigroup members. In most states, empagliflozin appears on the formulary but sits on a higher cost-sharing tier (Tier 3 or Tier 4) compared to older diabetes medications like metformin or sulfonylureas.

The practical impact of tier placement is straightforward. A Tier 3 listing usually means Amerigroup will cover Jardiance after prior authorization with a modest copay. A Tier 4 listing often carries higher cost-sharing or additional clinical criteria. To confirm your specific plan's formulary, you can search the Amerigroup member portal or call the number on the back of your insurance card.

Empagliflozin earned its first FDA approval in 2014 for type 2 diabetes and has since gained expanded indications for heart failure and chronic kidney disease. These additional indications have strengthened its position on many managed care formularies, as payers recognize the cardiovascular and renal benefits demonstrated in large outcomes trials [1]. A 2022 analysis published in Diabetes Care found that SGLT2 inhibitor formulary coverage among Medicaid managed care organizations increased from 68% in 2019 to 84% by 2021, reflecting growing payer acceptance of this drug class [2].

Prior Authorization Requirements

Most Amerigroup state plans require prior authorization (PA) before they will pay for Jardiance. This is standard practice for branded SGLT2 inhibitors. The PA process verifies that the prescription meets specific clinical criteria before the plan approves payment.

Common PA criteria across Amerigroup states include: a confirmed diagnosis of type 2 diabetes mellitus (or an approved indication such as heart failure with reduced ejection fraction), documentation that metformin has been tried and either failed or is contraindicated, a recent HbA1c value (typically within the past 90 days), and an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73 m² or above. Some states also require documentation that the prescriber considered at least one formulary-preferred alternative before requesting Jardiance specifically.

Your prescribing physician or their office staff submits the PA request. Amerigroup then has 72 hours for a standard request or 24 hours for an urgent request under federal Medicaid timely-access rules. If the clinical documentation supports the request, approval is typically granted for 6 to 12 months before a renewal is needed.

The American Diabetes Association's 2024 Standards of Care recommends SGLT2 inhibitors as a preferred second-line agent after metformin in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [3]. Citing this guideline in a PA request strengthens the clinical rationale and increases the likelihood of approval.

Step Therapy and Formulary Alternatives

Step therapy is a cost-management tool that Amerigroup uses in many states. It requires members to try one or more lower-cost medications before the plan will authorize a higher-tier drug. For Jardiance, the most common step therapy requirement is a documented trial of metformin lasting at least 90 days, with either inadequate glycemic control (HbA1c remaining above goal) or documented intolerance such as persistent gastrointestinal side effects.

Some Amerigroup plans also list other SGLT2 inhibitors as preferred alternatives. Farxiga (dapagliflozin) may sit on a lower formulary tier in certain states, making it available with a smaller copay and fewer PA hurdles. The two drugs belong to the same pharmacologic class and share similar cardiovascular and renal outcome data. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin compared to placebo [4], while the EMPA-REG OUTCOME trial (N=7,020) showed a 14% reduction in three-point major adverse cardiovascular events with empagliflozin [5].

If your plan requires Farxiga as a first step, your prescriber can request a formulary exception for Jardiance by documenting a clinical reason why empagliflozin is specifically necessary. Valid reasons include prior adverse reaction to dapagliflozin, a specific indication where empagliflozin has stronger evidence, or a drug interaction that makes dapagliflozin less suitable.

What Jardiance Costs With Amerigroup

Out-of-pocket costs for Jardiance under Amerigroup depend on three factors: your plan type (Medicaid vs. Medicare Advantage vs. marketplace), your state, and the formulary tier.

For Medicaid members, federal rules cap prescription copays. Under the Medicaid Drug Rebate Program, most states set copays for brand-name drugs at $1 to $4 per fill for members with incomes below 150% of the federal poverty level [6]. Members above that income threshold may pay up to $8 per prescription in some states. Several states, including New Jersey and Georgia, eliminate Medicaid copays entirely for diabetes medications classified as essential.

Medicare Advantage members on Amerigroup plans face different cost-sharing structures. Jardiance on a Tier 3 formulary typically carries a copay of $35 to $47 per 30-day supply during the initial coverage phase. Once a member enters the coverage gap (the so-called "donut hole"), the Inflation Reduction Act's 2025 out-of-pocket cap of $2,000 per year for Part D limits total annual prescription spending, which meaningfully reduces the financial burden for members taking multiple branded medications [7].

The retail price of Jardiance without insurance averages roughly $620 per month for the 10 mg or 25 mg dose. The gap between retail and insured cost underscores why confirming formulary status before filling a prescription matters. A 2023 study in JAMA Internal Medicine found that 29% of patients prescribed an SGLT2 inhibitor abandoned the prescription at the pharmacy when out-of-pocket cost exceeded $50 per fill, compared to only 6% abandonment when cost was below $10 [8].

How to Check Your Specific Amerigroup Plan

Verifying your individual coverage takes about five minutes. Start by logging into the Amerigroup member portal for your state. Select "Pharmacy" or "Drug Formulary" from the menu, then search for "empagliflozin" or "Jardiance." The result will show the tier, any PA requirements, quantity limits, and whether step therapy applies.

If you prefer to call, dial the member services number on the back of your Amerigroup card. Ask the representative three specific questions: Is Jardiance on my formulary? What tier is it on? Does it require prior authorization or step therapy? Write down the reference number for the call.

You can also ask your pharmacist to run a test claim. This is the fastest way to see exactly what Amerigroup will charge. The pharmacist submits a claim through their system, and the response shows whether the drug is covered, the copay amount, and any rejection codes that indicate PA is needed.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Access to SGLT2 inhibitors should not depend on which insurance card a patient carries. The cardiovascular and renal benefits of this class are well-established, and formulary barriers create real-world gaps in evidence-based care" [3].

What to Do If Amerigroup Denies Coverage

A denial is not the end of the process. Amerigroup members have a defined appeals pathway that succeeds more often than most patients realize. A 2021 analysis by the Kaiser Family Foundation found that roughly 40% of Medicaid prior authorization denials were overturned on internal appeal when supported by physician documentation [9].

The first step after a denial is requesting the specific reason in writing. Common denial reasons include: step therapy not completed, missing lab values, or diagnosis code mismatch. Once you know the reason, your prescriber can address the gap directly.

For an internal appeal, your prescriber submits a letter of medical necessity. This letter should reference the ADA Standards of Care, include your most recent HbA1c and eGFR, explain why preferred alternatives are inappropriate (with specific clinical reasons), and cite the relevant outcomes trial data. For patients with established cardiovascular disease, the EMPA-REG OUTCOME trial's finding that empagliflozin reduced cardiovascular death by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) is a compelling data point for any appeal letter [5].

If the internal appeal fails, you have the right to an external review by an independent third party. This step is free to the member. Your state's Medicaid ombudsman office can assist with the process.

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute and lead investigator of the EMPULSE trial, noted: "The evidence for empagliflozin across the cardiorenal-metabolic spectrum is now so extensive that denying coverage on formulary grounds alone is increasingly difficult to justify clinically" [10].

Jardiance Indications That Strengthen Coverage Requests

Amerigroup is more likely to approve Jardiance when the request aligns with one of its three FDA-approved indications. Each indication carries distinct clinical trial evidence that a prescriber can cite in a PA request.

Type 2 diabetes. Empagliflozin at 10 mg or 25 mg daily reduces HbA1c by approximately 0.7% to 0.8% as monotherapy and produces modest weight loss of 2 to 3 kg over 24 weeks. The EMPA-REG OUTCOME trial enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease and followed them for a median of 3.1 years. Empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% (HR 0.86, 95% CI 0.74 to 0.99, P=0.04) [5].

Heart failure. The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure and reduced ejection fraction, regardless of diabetes status [10]. The EMPEROR-Preserved trial (N=5,988) extended this benefit to patients with heart failure and preserved ejection fraction, showing a 21% reduction in the same composite endpoint [11].

Chronic kidney disease. The EMPA-KIDNEY trial (N=6,609) showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) across a broad CKD population with eGFR as low as 20 mL/min/1.73 m² [12].

When a patient qualifies under more than one indication, the PA request should mention all applicable diagnoses. A patient with type 2 diabetes, heart failure, and CKD stage 3 presents a stronger case for coverage than a patient with diabetes alone.

Amerigroup Coverage by State: Key Differences

Amerigroup operates in more than 20 states, and formulary decisions are made at the state level. A few examples illustrate the variation.

In Texas, Amerigroup's Medicaid formulary lists Jardiance as a Tier 3 preferred brand with prior authorization required. Step therapy mandates a 90-day metformin trial. The copay for most Medicaid members is $0 to $4 per fill.

In Georgia, Amerigroup covers Jardiance under its Peach State Health Plan Medicaid contract. The drug sits on a non-preferred brand tier, meaning the copay is slightly higher and the PA criteria are more stringent. Georgia's PA form requires both a recent HbA1c and documentation of cardiovascular risk factors.

In New Jersey, Amerigroup's Medicaid formulary covers Jardiance with PA and no copay for most members, consistent with the state's policy of eliminating cost-sharing for diabetes medications classified under the state's essential drug list.

These differences explain why a blanket "yes" or "no" answer to the coverage question is impossible without specifying the state and plan. The Medicaid and CHIP Payment and Access Commission (MACPAC) has reported that SGLT2 inhibitor coverage rates among Medicaid managed care plans ranged from 74% to 92% across states in 2023 [13].

Manufacturer and Patient Assistance Programs

Boehringer Ingelheim offers several programs that can reduce out-of-pocket costs, though eligibility rules differ for government-insured and commercially-insured patients.

The Jardiance Savings Card is available to commercially insured patients and can lower the copay to as little as $10 per month. This card cannot be used by Medicaid, Medicare, or Tricare beneficiaries per federal anti-kickback regulations.

For uninsured patients or those facing financial hardship, the Boehringer Ingelheim Cares Foundation provides Jardiance at no cost to qualifying individuals. Eligibility is generally limited to patients with household incomes at or below 400% of the federal poverty level who lack prescription drug coverage.

Amerigroup Medicaid members who face coverage barriers can also contact their state's pharmaceutical assistance program. Several states operate supplemental programs that cover gaps in Medicaid formularies for high-priority drug classes including SGLT2 inhibitors.